comparemela.com

Page 2 - Sylvie Berrebi Mark News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022

Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

Enterome s OncoMimics peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Memory CD8+ T cell response found as early as two weeks after the first administration of EO2401, expanding to up to 5% of circulating specific CD8+ T cells in some patients Immunological

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.